Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV)
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …

Zika virus, influenza, and Ebola have called attention to the ways in which infectious disease
outbreaks can severely–and at times uniquely–affect the health interests of pregnant women …

HPV-023 (NCT00518336; ClinicalTrial. gov) is a long-term follow-up of an initial double-
blind, randomized (1: 1), placebo-controlled study (HPV-001, NCT00689741) evaluating the …

Background Three-dose regimens for human papillomavirus (HPV) vaccines are expensive
and difficult to complete, especially in settings where the need for cervical cancer prevention …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

In this paper, we review the published evidence about the long-term efficacy of the available
human papillomavirus (HPV) vaccines and their safety profile. Two prophylactic HPV …

Background Anal cancer remains rare (incidence of about 1· 5 per 100 000 women yearly),
but rates are increasing in many countries. Human papillomavirus (HPV) 16 and 18 …

The human papilloma virus (HPV) infection, caused by a ubiquitous virus typically
transmitted through the direct contact of infected organs, either through the skin or mucosa …

Human papillomavirus (HPV) is the most common sexually transmitted infectious agent; its
14 oncogenic types are causally associated with 5–10% of all cancers. The major structural …